Submitted by olivia-rzadkiewicz on Tue, 12/04/2016 - 16:17
GW Pharmaceuticals has announced the start of a Phase 3 clinical trial of Epidiolex® (a cannabidiol-based medication) as an adjunctive therapy for the treatment of epileptic seizures in the rare genetic disorder tuberous sclerosis complex (TSC).
